ART Need and Coverage
VF AND HIV DRUG RESISTANCE: NO SMALL PROBLEM
Key Clinical / Programmatic Questions
34 million people living with HIV
23.5 M (2/3) in SSA
5.6 M (16%) in SA
16.7 million people need ART*
11 M in SSA
2.5 M in SA
9.7 million people receiving ART
7.5 M in SSA (68%)
2.1 M in SA (84%)
23.5 M (2/3) in SSA
5.6 M (16%) in SA
16.7 million people need ART*
11 M in SSA
2.5 M in SA
9.7 million people receiving ART
7.5 M in SSA (68%)
2.1 M in SA (84%)
Worldwide estimates of 3-30% virologic failure within one year of first ART (500K – 5M)*
40-95% individuals VF have > 1 major resistance mutation
1.2-25.5% of individuals on ART will have drug resistance within one year (200K – 4.3M)*
Over time triple class failure will accumulate
40-95% individuals VF have > 1 major resistance mutation
1.2-25.5% of individuals on ART will have drug resistance within one year (200K – 4.3M)*
Over time triple class failure will accumulate
Can we predict which patients are likely to experience virologic failure?
Before starting
While on treatment
Can we prevent these patients from experiencing virologic failure?
Before starting
While on treatment
Can we prevent these patients from experiencing virologic failure?
